Spinal muscular atrophy: mechanisms and therapeutic strategies.

Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder and a leading genetic cause of infantile mortality. SMA is caused by mutation or deletion of Survival Motor Neuron-1 (SMN1). The clinical features of the disease are caused by specific degeneration of alpha-motor neurons in the spinal cord, leading to muscle weakness, atrophy and, in the majority of cases, premature death. A highly homologous copy gene (SMN2) is retained in almost all SMA patients but fails to generate adequate levels of SMN protein due to its defective splicing pattern. The severity of the SMA phenotype is inversely correlated with SMN2 copy number and the level of full-length SMN protein produced by SMN2 ( approximately 10-15% compared with SMN1). The natural history of SMA has been altered over the past several decades, primarily through supportive care measures, but an effective treatment does not presently exist. However, the common genetic etiology and recent progress in pre-clinical models suggest that SMA is well-suited for the development of therapeutic regimens. We summarize recent advances in translational research that hold promise for the progression towards clinical trials.

[1]  B. Wirth,et al.  SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. , 2010, Human molecular genetics.

[2]  M. Gurney,et al.  Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. , 2010, Human molecular genetics.

[3]  S. Salani,et al.  Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. , 2010, Brain : a journal of neurology.

[4]  C. Lorson,et al.  Trans-Splicing-Mediated Improvement in a Severe Mouse Model of Spinal Muscular Atrophy , 2010, The Journal of Neuroscience.

[5]  T. Geib,et al.  Restoration of Full-Length SMN Promoted by Adenoviral Vectors Expressing RNA Antisense Oligonucleotides Embedded in U7 snRNAs , 2009, PloS one.

[6]  C. Lorson,et al.  Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA , 2009, BMC Neuroscience.

[7]  David R. Liu,et al.  A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. , 2009, Cell stem cell.

[8]  Yan Leng,et al.  Multiple roles of HDAC inhibition in neurodegenerative conditions , 2009, Trends in Neurosciences.

[9]  C. Lorson,et al.  Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. , 2009, Human molecular genetics.

[10]  B. Wirth,et al.  LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. , 2009, Human molecular genetics.

[11]  S. Salani,et al.  Motoneuron Transplantation Rescues the Phenotype of SMARD1 (Spinal Muscular Atrophy with Respiratory Distress Type 1) , 2009, The Journal of Neuroscience.

[12]  C. Lutz,et al.  Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. , 2009, Human molecular genetics.

[13]  D. Chandler,et al.  Intron 7 conserved sequence elements regulate the splicing of the SMN genes , 2009, Human Genetics.

[14]  C. Beattie,et al.  Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? , 2009, Nature Reviews Neuroscience.

[15]  L. Gangwani,et al.  A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy , 2009, RNA biology.

[16]  J. Fyfe,et al.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  G. Lutz,et al.  Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy , 2009, The Journal of Neuroscience.

[18]  Robert Lanza,et al.  Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. , 2009, Cell stem cell.

[19]  Peter G Schultz,et al.  Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4 , 2009, Proceedings of the National Academy of Sciences.

[20]  M. Schroth,et al.  Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy , 2009, PloS one.

[21]  Dong Wook Han,et al.  Generation of induced pluripotent stem cells using recombinant proteins. , 2009, Cell stem cell.

[22]  C. Lorson,et al.  Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. , 2009, Human molecular genetics.

[23]  Wei Wang,et al.  piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells , 2009, Nature.

[24]  C. Heier,et al.  Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. , 2009, Human molecular genetics.

[25]  Adrian R Krainer,et al.  Splicing therapeutics in SMN2 and APOB. , 2009, Current opinion in molecular therapeutics.

[26]  A. Bradley,et al.  Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon , 2009, Nature Methods.

[27]  C. Lorson,et al.  Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. , 2009, Human molecular genetics.

[28]  K. Woltjen,et al.  Virus free induction of pluripotency and subsequent excision of reprogramming factors , 2009, Nature.

[29]  D. Trono,et al.  Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. , 2009, Human molecular genetics.

[30]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[31]  Yanhong Shi.  Induced pluripotent stem cells, new tools for drug discovery and new hope for stem cell therapies. , 2009, Current molecular pharmacology.

[32]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[33]  Ching H. Wang,et al.  Spinal muscular atrophy: Advances in research and consensus on care of patients , 2008, Current treatment options in neurology.

[34]  M. Gurney,et al.  DcpS as a therapeutic target for spinal muscular atrophy. , 2008, ACS chemical biology.

[35]  C. Lorson,et al.  A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. , 2008, Human gene therapy.

[36]  C. Lorson,et al.  Development of a Single Vector System that Enhances Trans-Splicing of SMN2 Transcripts , 2008, PloS one.

[37]  Barrington G. Burnett,et al.  Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition , 2008, Annals of neurology.

[38]  R. Lu,et al.  The RNA Binding Protein hnRNP Q Modulates the Utilization of Exon 7 in the Survival Motor Neuron 2 (SMN2) Gene , 2008, Molecular and Cellular Biology.

[39]  Eitan Kerem,et al.  Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial , 2008, The Lancet.

[40]  Hynek Wichterle,et al.  Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.

[41]  L. Tsai,et al.  Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice , 2008, Journal of Molecular Medicine.

[42]  Darrell N. Kotton,et al.  Figure 3 , 2008 .

[43]  B. Wirth,et al.  Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy , 2008, Science.

[44]  T. Crawford,et al.  Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. , 2008, Human molecular genetics.

[45]  Y. Hua,et al.  Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. , 2008, American journal of human genetics.

[46]  M. Gurney,et al.  Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. , 2008, Journal of medicinal chemistry.

[47]  G. Levy,et al.  The changing natural history of spinal muscular atrophy type 1 , 2007, Neurology.

[48]  B. Rothen‐Rutishauser,et al.  Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  C. Lorson,et al.  Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  C. DiDonato,et al.  Animal Models of Spinal Muscular Atrophy , 2007, Journal of child neurology.

[51]  M. Wood,et al.  Modulating the Expression of Disease Genes with RNA-Based Therapy , 2007, PLoS genetics.

[52]  R. Singh.  Unfolding the mystery of alternative splicing through a unique method of in vivo selection. , 2007, Frontiers in bioscience : a journal and virtual library.

[53]  R. Lund,et al.  Protection of Visual Functions by Human Neural Progenitors in a Rat Model of Retinal Disease , 2007, PloS one.

[54]  Brenda F Baker,et al.  Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon , 2007, PLoS biology.

[55]  K. Fischbeck,et al.  Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. , 2007, The Journal of clinical investigation.

[56]  J. Manley,et al.  An intronic element contributes to splicing repression in spinal muscular atrophy , 2007, Proceedings of the National Academy of Sciences.

[57]  A. D'Amico,et al.  Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy , 2007, Neurology.

[58]  E. Androphy,et al.  Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes , 2006, Nucleic acids research.

[59]  D. Kerr,et al.  Cellular therapies in motor neuron diseases. , 2006, Biochimica et biophysica acta.

[60]  C. Lorson,et al.  Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts , 2006, Human Genetics.

[61]  C. Lorson,et al.  Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[62]  R. Sidman,et al.  Purkinje neuron degeneration in nervous (nr) mutant mice is mediated by a metabolic pathway involving excess tissue plasminogen activator , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[63]  E. Androphy,et al.  Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron , 2006, Molecular and Cellular Biology.

[64]  T. Geib,et al.  Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  Xiaocun Chen,et al.  Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. , 2005, Human molecular genetics.

[66]  C. Lorson,et al.  A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. , 2005, Human molecular genetics.

[67]  Y. Hua,et al.  Modulation of SMN nuclear foci and cytoplasmic localization by its C-terminus , 2004, Cellular and Molecular Life Sciences CMLS.

[68]  K. Sangkuhl,et al.  Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. , 2004, Human molecular genetics.

[69]  E. Androphy,et al.  An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy. , 2004, Biochemical and biophysical research communications.

[70]  J. Manley,et al.  A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy , 2003, Nature Genetics.

[71]  Jeffrey D. Rothstein,et al.  Human Embryonic Germ Cell Derivatives Facilitate Motor Recovery of Rats with Diffuse Motor Neuron Injury , 2003, The Journal of Neuroscience.

[72]  F. Muntoni,et al.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[73]  A. Krainer,et al.  Correction of disease-associated exon skipping by synthetic exon-specific activators , 2003, Nature Structural Biology.

[74]  Y. Hofmann,et al.  hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1. , 2002, Human molecular genetics.

[75]  K. Imaizumi,et al.  Identification of a Cis-acting Element for the Regulation ofSMN Exon 7 Splicing* , 2002, The Journal of Biological Chemistry.

[76]  A. Krainer,et al.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 , 2002, Nature Genetics.

[77]  C. Lorson,et al.  SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2 beta 1. , 2002, Human molecular genetics.

[78]  T. Wienker,et al.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. , 2002, American journal of human genetics.

[79]  Sharlene R. Lim,et al.  Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3′ Splice Site Pairing* , 2001, The Journal of Biological Chemistry.

[80]  Y. Jong,et al.  Treatment of spinal muscular atrophy by sodium butyrate , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[81]  N. Gilbert,et al.  SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens , 2001, Human Genetics.

[82]  S. Stamm,et al.  Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[83]  C. Lorson,et al.  An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. , 2000, Human molecular genetics.

[84]  B. Dallapiccola,et al.  Expression study of survival motor neuron gene in human fetal tissues. , 1997, Biochemical and molecular medicine.

[85]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.